World of DTC Marketing

MARCH 17, 2021

The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.

Pharma 186

Pharma Competition Prescription Sales 186

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 110

Biopharma Sales Prescription FDA 110

Pharmaceutical Technology

SEPTEMBER 15, 2022

The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. YoY revenue growth.

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing. per-share deal valuing GBT at $5.4

Marketing 111

Marketing Sales Pharma FDA 111

Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year.

Patients 111

Patients Safety Sales Manufacturing 111

Pharmaceutical Technology

MAY 16, 2023

trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.

Marketing 52

Marketing Sales Pharma Leads 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

pharmaphorum

JANUARY 5, 2023

A new operating model for pharma shifted priorities and forced companies to rethink their organisational strategies. Everything from transitioning to virtual meetings with healthcare providers, to navigating the logistics of supply chain disruptions, has permanently altered pharma operations – many would say for the better.

Pharmaceutical 90

Pharmaceutical Recruitment Training Education 90

Pharmaceutical Technology

NOVEMBER 8, 2022

Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy Life Sciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year.

Food and Drug Administration 59

Food and Drug Administration Leads Pharma Food 59

European Pharmaceutical Review

MAY 2, 2023

Astellas Pharma has agreed to acquire ophthalmology biotech company Iveric Bio, Inc. The acquisition “seems to be the biggest” in the company ‘s history, Prashant Khadayate, Pharma Analyst at GlobalData observed. Avacincaptad pegol is forecasted to achieve sales of $1.09 for approximately $5.9

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

pharmaphorum

AUGUST 2, 2022

As the technology has developed, the interest from larger pharma companies has continued to grow, resulting in a number of acquisitions and partnerships taking place to gain access to the technology. Looking to the future. billion in revenue last year.

Marketing 98

Marketing Prospecting Sales Pharma 98

Pharmaceutical Technology

SEPTEMBER 2, 2022

Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. According to GlobalData’s consensus analyst sales and forecast database, Carvykti is forecast to achieve the highest sales of the anti-BCMA biologics class, with $2.9

Food and Drug Administration 59

Food and Drug Administration FDA Sales Marketing 59

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

JULY 12, 2022

The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

pharmaphorum

NOVEMBER 2, 2022

.” The deal also ties in with J&J’s plan to boost the margins it makes from its medical device and pharma divisions as it prepares to spin off its slower-growing consumer health business before the end of 2023 and chases down target revenues of $60 billion in 2025. Impella heart pump. Joaquin Duato.

Sales 52

Sales Medical Marketing Manufacturing 52

Pharmaceutical Technology

JANUARY 19, 2023

GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 52

Marketing FDA Sales Management 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

FEBRUARY 13, 2023

According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.

Competition 59

Competition Safety Patients Pharmaceutical 59

Contrarian Sales Techniques

FEBRUARY 10, 2023

According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028. This growth is driven by several factors, including: 1.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

pharmaphorum

AUGUST 4, 2022

The $52-per-share offer would give Amgen a drug that some analysts have described as a pipeline in a pill with $1 billion-plus sales potential, and is a sizeable premium on ChemoCentryx’ pre-deal announcement share price of just over $24. billion bid to buy out the company.

Side effects 98

Side effects Sales Pharma Competition 98

pharmaphorum

JULY 7, 2022

Reaching an agreement may just be the first hurdle, given both companies’ prominence in oncology which may raise antitrust issues with financial regulators – something that has already delayed some big deals in the pharma sector.

Pharma 52

Pharma Marketing Sales Medicine 52